[
  {
    "ts": null,
    "headline": "Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?",
    "summary": "Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Zoetis (NYSE: ZTS) as worthy of further study and has named Zoetis its \"Stock to Study\" for the March 2025 issue for investors' informational and educational use.",
    "url": "https://finnhub.io/api/news?id=909d8cd38a0a98c18a9c0f6c2fae6883e47aa58876e7daa2e73371e9e85d632d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736284500,
      "headline": "Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?",
      "id": 132307076,
      "image": "https://media.zenfs.com/en/prnewswire.com/69307fac50198407debe89c4c5213600",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Zoetis (NYSE: ZTS) as worthy of further study and has named Zoetis its \"Stock to Study\" for the March 2025 issue for investors' informational and educational use.",
      "url": "https://finnhub.io/api/news?id=909d8cd38a0a98c18a9c0f6c2fae6883e47aa58876e7daa2e73371e9e85d632d"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Zoetis Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=75de56718dc692348ed90bedc3d479270d244d6a7f936b35f40fffb8864b7565",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736268420,
      "headline": "Zoetis Inc. stock underperforms Tuesday when compared to competitors",
      "id": 132327394,
      "image": "",
      "related": "ZTS",
      "source": "MarketWatch",
      "summary": "Zoetis Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=75de56718dc692348ed90bedc3d479270d244d6a7f936b35f40fffb8864b7565"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results",
    "summary": "PARSIPPANY, N.J., January 07, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the call.",
    "url": "https://finnhub.io/api/news?id=c74f93890ed3ef79146456d613b11cad1f0ac40e0d70e4d36c8f5b51de7022e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736256600,
      "headline": "Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results",
      "id": 132307077,
      "image": "https://media.zenfs.com/en/business-wire.com/b95d996a5d96c99b98d66d0a601ef9ef",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "PARSIPPANY, N.J., January 07, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the call.",
      "url": "https://finnhub.io/api/news?id=c74f93890ed3ef79146456d613b11cad1f0ac40e0d70e4d36c8f5b51de7022e2"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "ZTS",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth Strategy Q4 2024 Commentary",
    "summary": "In a period of momentum-driven returns and bullish investor sentiment sparked by the re-election of Donald Trump, the more defensively positioned Strategy underperformed.",
    "url": "https://finnhub.io/api/news?id=e1daac718535fa1c98749ddca4d274be967f91e2f351129eb0739e003c46acc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736245200,
      "headline": "ClearBridge Large Cap Growth Strategy Q4 2024 Commentary",
      "id": 132301203,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/117247268/image_117247268.jpg?io=getty-c-w1536",
      "related": "ZTS",
      "source": "SeekingAlpha",
      "summary": "In a period of momentum-driven returns and bullish investor sentiment sparked by the re-election of Donald Trump, the more defensively positioned Strategy underperformed.",
      "url": "https://finnhub.io/api/news?id=e1daac718535fa1c98749ddca4d274be967f91e2f351129eb0739e003c46acc2"
    }
  }
]